TextSearch

Which COVID Vaccine You Get Can Impact Myocarditis Risk - American College of Cardiology

Which COVID Vaccine You Get Can Impact Myocarditis Risk - American College of Cardiology ClearSearchLoading Create Free Account or Log in to MyACC Menu Home Guidelines JACC ACC.23/WCC Members About Join Clinical Topics Acute Coronary Syndromes Anticoagulation Management Arrhythmias and Clinical EP Cardiac Surgery Cardio-Oncology Cardiovascular Care Team Congenital Heart Disease and Pediatric Cardiology COVID-19 Hub Diabetes and Cardiometabolic Disease Dyslipidemia Geriatric Cardiology Heart Failure and Cardiomyopathies Invasive Cardiovascular Angiography and Intervention Noninvasive Imaging Pericardial Disease Prevention Pulmonary Hypertension and Venous Thromboembolism Sports and Exercise Cardiology Stable Ischemic Heart Disease Valvular Heart Disease Vascular Medicine Latest In Cardiology Clinical Updates & Discoveries Advocacy & Policy Perspectives & Analysis Meeting Coverage ACC Member Publications ACC Podcasts View All Cardiology Updates Education and Meetings Online Learning Catalog Earn Credit Board Prep Offerings View the Education Catalog Products ACC Anywhere: The Cardiology Video Library ACCSAP ACCEL CardioSource Plus for Institutions and Practices CathSAP ECG Drill and Practice EchoSAP EP SAP HF SAP Heart Songs Nuclear Cardiology Online Courses Collaborative Maintenance Pathway (CMP) Resources Guideline Education Understanding MOC Image and Slide Gallery Meetings Annual Scientific Session and Related Events Chapter Meetings Live Meetings Live Meetings - International Webinars - Live Webinars - OnDemand Tools and Practice Support ACC Accreditation Services ACC Quality Improvement for Institutions Program CardioSmart National Cardiovascular Data Registry (NCDR) MedAxiom Advocacy at the ACC Cardiology as a Career Path Cardiology Careers Cardiovascular Buyers Guide Clinical Solutions Clinician Well-Being Portal Diversity and Inclusion Infographics Mobile and Web Apps Quality Programs < Back to Listings Which COVID Vaccine You Get Can Impact Myocarditis Risk Study shows higher rates of heart inflammation with Moderna vs. Pfizer, but overall risk still very low Nov 07, 2022 Share via: AddThis Sharing ButtonsShare to FacebookFacebookShare to TwitterTwitterShare to LinkedInLinkedInShare to EmailEmailShare to MoreAddThis19 Print Font Size A A A Contact: Nicole Napoli, [email protected], 202-375-6523 WASHINGTON (Nov 07, 2022) - Incidence of myocarditis, pericarditis or myopericarditis is two- to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine when compared to the Pfizer BioNTech COVID-19 vaccine; however, overall cases of heart inflammation with either vaccine are very rare, according to a study in the Journal of the American College of Cardiology. The study showed males younger than 40 years old who received the Moderna vaccine were shown to have the highest rates of myocarditis, which according to the authors, may have implications for choosing specific vaccines for certain populations. Two mRNA COVID-19 vaccines have been approved for use, Pfizer BioNTech (BNT162b2) and Moderna Spikevax (mRNA-1273), and as of March 20, 2022, more than 52 million doses of Pfizer and 22 million doses of Moderna have been administered in Canada, where this study was conducted. Clinical trials have demonstrated the vaccines are safe and monitoring of vaccinated people has shown side effects are mild and go away on their own. However, some rare, but serious, side effects have been observed after both vaccines, mainly myocarditis (inflammation of the heart). While there have been many studies on either vaccine, few studies have been conducted to directly compare the safety of the two mRNA vaccines. Researchers in this study sought to compare the risk of myocarditis, pericarditis and myopericarditis between the Pfizer and Moderna COVID-19 vaccines. People in the study were 18 years old or older and had received two primary doses of either Pfizer or Moderna vaccine in British Columbia, Canada, with the second dose between Jan. 1, 2021 and Sept. 9, 2021. Individuals whose first or second shot were administered outside of British Columbia or had a history of myocarditis or pericarditis within one year prior to second dose were excluded. In all, more than 2.2 million second Pfizer doses were given and more than 870,000 Moderna doses. Within 21 days of the second dose, there were a total of 59 myocarditis cases (21 Pfizer and 31 Moderna) and 41 pericarditis cases (21 Pfizer and 20 Moderna). Researchers also looked at rates per million doses and the rate was 35.6 cases per million for Moderna and 12.6 per million for Pfizer—an almost threefold increase after Moderna shots vs. Pfizer. Comparatively, rates of myocarditis in the general population in 2018, were 2.01 per million in people under age 40 and 2.2 per million in people over age 40. Rates of myocarditis and pericarditis were higher with the Moderna vaccine in both males and females between ages 18 and 39, with the highest per million rates in males ages 18-29 after a second dose of Moderna. According to the authors, the findings support recommending certain populations receive certain vaccines to maximize benefits and minimize adverse events. “Few population-based analyses have been conducted to directly compare the safety of the two mRNA COVID-19 vaccines, which differ in important ways that could impact safety,” said Naveed Janjua, MBBS, DrPH, lead author of the study and an epidemiologist and the executive director of Data and Analytic Services at the British Columbia Centre for Disease Control. “Our findings have implications for strategizing the rollout of mRNA vaccines, which should also consider the self-limiting and mild nature of most myocarditis events, benefits provided by vaccination, higher effectiveness of the Moderna vaccine against infection and hospitalization [found in prior studies], and the apparent higher risk of myocarditis following COVID-19 infection than with mRNA vaccination.” Limitations of the study include that it was observational, which limits the ability to determine causality between vaccination and myocarditis or pericarditis. However, temporality was ensured in the study design to limit the time studied between vaccine dose and myocarditis/pericarditis diagnosis. Also, the study relied on hospital and emergency department visit data and may have missed some less severe cases.  In a related editorial comment, Guy Witberg, MD, MPH, a cardiologist at Rabin Medical Center in Petah-Tikva, Israel, wrote the study is reassuring for vaccine safety since it provides further data that myocarditis is a very rare adverse event after both vaccines, and it is an important step toward a personalized approach to administering COVID-19 vaccines. “[The study] should help put to rest ‘vaccine hesitancy’ due to concerns over cardiac adverse events,” Witberg said. “This is one of only a few direct comparisons of the two widely adopted mRNA vaccines, and its results have practical policy implications: for a substantial segment of the population suffering from cardiovascular disease…these data give a strong argument to preferentially use the BNT162b2 [Pfizer] vaccine over mRNA-1273 [Moderna].” The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 56,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.  The ACC’s family of JACC Journals rank among the top cardiovascular journals in the world for scientific impact. The flagship journal, the Journal of the American College of Cardiology (JACC) — and family of specialty journals consisting of JACC: Advances, JACC: Asia, JACC: Basic to Translational Science, JACC: CardioOncology, JACC: Cardiovascular Imaging, JACC: Cardiovascular Interventions, JACC: Case Reports, JACC: Clinical Electrophysiology and JACC: Heart Failure — pride themselves on publishing the top peer-reviewed research on all aspects of cardiovascular disease. Learn more at JACC.org. ### Share via: AddThis Sharing ButtonsShare to FacebookFacebookShare to TwitterTwitterShare to LinkedInLinkedInShare to EmailEmailShare to MoreAddThis19 < Back to Listings YOU ARE HERE: Home > About ACC > Press Releases > Which-COVID-Vaccine-You-Get-Can-Impact-Myocarditis-Risk Guidelines JACC Journals on ACC.org JACC JACC: Advances JACC: Asia JACC: Basic to Translational Science JACC: CardioOncology JACC: Cardiovascular Imaging JACC: Cardiovascular Interventions JACC: Case Reports JACC: Clinical Electrophysiology JACC: Heart Failure Membership Current Members Campaign for the Future Become a Member Renew Your Membership Member Benefits and Resources Member Sections Chapters ACC Member Directory About ACC ACC Innovation Program Our Strategic Direction Diversity and Inclusion Our History Our Bylaws and Code of Ethics Leadership and Governance Industry Relations Support the ACC Jobs at the ACC Press Releases Social Media Book Our Conference Center Clinical Topics Acute Coronary Syndromes Anticoagulation Management Arrhythmias and Clinical EP Cardiac Surgery Cardio-Oncology Chronic Angina Congenital Heart Disease and     Pediatric Cardiology COVID-19 Hub Diabetes and Cardiometabolic     Disease Dyslipidemia Geriatric Cardiology Heart Failure and Cardiomyopathies Hypertriglyceridemia Invasive Cardiovascular Angiography    and Intervention Noninvasive Imaging Pericardial Disease Prevention Pulmonary Hypertension and Venous     Thromboembolism Sports and Exercise Cardiology Stable Ischemic Heart Disease Valvular Heart Disease Vascular Medicine Latest in Cardiology Clinical Updates & Discoveries Advocacy & Policy Perspectives & Analysis Meeting Coverage ACC Member Publications ACC Podcasts Education and Meetings Online Learning Catalog Understanding MOC Products and Resources Image and Slide Gallery Meetings Annual Scientific Session Tools and Practice Support Quality Improvement for Institutions NCDR CardioSmart Accreditation Services Clinical Solutions Clinician Well-Being Portal Diversity and Inclusion Mobile and Web Apps Advocacy at the ACC Cardiology as a Career Path Cardiology Careers Practice Solutions Quality Programs JACC Quality Improvement for Institutions NCDR CardioSmart MedAxiom Accreditation Services Contact Us Heart House 2400 N. St. NW Washington, DC 20037 Email: [email protected] Phone: (202) 375-6000 Toll Free: (800) 253-4636 Fax: (202) 375-7000 Media Center ACC.org Quick Start Guide Advertising & Sponsorship Policy Clinical Content Disclaimer Editorial Board Privacy Policy Registered User Agreement Terms of Service Cookie Policy Site Map © 2023 American College of Cardiology Foundation. All rights reserved. This site uses cookies to improve your experience. By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Service. OK We'd welcome your feedback! Would you take a brief survey so we can improve your experience on ACC.org? Yes, I'll give feedback No thanks Powered by Verint Experience Cloud ShareThis Copy and Paste